Corticobasal Degeneration

 

 Buy Article Permissions and Reprints

Abstract

Among the atypical parkinsonian syndromes, corticobasal degeneration (CBD) is probably the most challenging disorder to diagnose antemortem. It can present with multiple phenotypes, none of them specific enough to lead to an unequivocal diagnosis. Alternatively, multiple other neurodegenerative disorders with a different underlying pathology, such as Alzheimer disease (AD), can mimic its clinical course. The ultimate etiology of CBD is unknown; however, current neuropathological and genetic evidence support a role for microtubule-associated protein tau. The classic clinical presentation is corticobasal syndrome, which typically presents as an asymmetric parkinsonism with a variable combination of ideomotor apraxia, rigidity, myoclonus, and dystonia, often associated with the presence of an alien limb phenomenon. Recently, a new set of diagnostic criteria has been developed, but still definite diagnosis requires autopsy confirmation. At the present time, no disease modifying therapies are available, but extensive research is being conducted.

• References

• 1 Armstrong MJ, Litvan I, Lang AE , et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80 (5) 496-503
  CrossrefPubMedGoogle Scholar
• 2 Dickson DW, Bergeron C, Chin SS , et al; Office of Rare Diseases of the National Institutes of Health. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002; 61 (11) 935-946
  CrossrefPubMedGoogle Scholar
• 3 Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol 2011; 7 (5) 263-272
  CrossrefPubMedGoogle Scholar
• 4 Dickson DH, Hauw J-J, Agid Y, Litvan I. Progressive supranuclear palsy and corticobasal degeneration. In Dickson DW, Weller RO, , eds. Neurodegeneration. 2nd ed. Hoboken, NJ: Wiley/Blackwell; 2011
  CrossrefGoogle Scholar
• 5 Kouri N, Murray ME, Hassan A , et al. Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain 2011; 134 (Pt 11) 3264-3275
  CrossrefPubMedGoogle Scholar
• 6 Dickson DW. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999; 246 (Suppl. 02) II6-II15
  CrossrefPubMedGoogle Scholar
• 7 Boeve BF. The multiple phenotypes of corticobasal syndrome and corticobasal degeneration: implications for further study. J Mol Neurosci 2011; 45 (3) 350-353
  CrossrefPubMedGoogle Scholar
• 8 Rebeiz JJ, Kolodny EH, Richardson Jr EP. Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life. Trans Am Neurol Assoc 1967; 92: 23-26
  PubMedGoogle Scholar
• 9 Rebeiz JJ, Kolodny EH, Richardson Jr EP. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968; 18 (1) 20-33
  CrossrefPubMedGoogle Scholar
• 10 Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 38-1985. A 66-year-old man with progressive neurologic deterioration. N Engl J Med 1985; 313 (12) 739-748
  CrossrefPubMedGoogle Scholar
• 11 Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain 1989; 112 (Pt 5) 1171-1192
  CrossrefPubMedGoogle Scholar
• 12 Chand P, Grafman J, Dickson D, Ishizawa K, Litvan I. Alzheimer's disease presenting as corticobasal syndrome. Mov Disord 2006; 21 (11) 2018-2022
  CrossrefPubMedGoogle Scholar
• 13 Lang AE, Bergeron C, Pollanen MS, Ashby P. Parietal Pick's disease mimicking cortical-basal ganglionic degeneration. Neurology 1994; 44 (8) 1436-1440
  CrossrefPubMedGoogle Scholar
• 14 Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003; 54 (Suppl. 05) S15-S19
  CrossrefPubMedGoogle Scholar
• 15 Litvan I. Progressive supranuclear palsy and corticobasal degeneration. Baillieres Clin Neurol 1997; 6 (1) 167-185
  PubMedGoogle Scholar
• 16 Togasaki DM, Tanner CM. Epidemiologic aspects. Adv Neurol 2000; 82: 53-59
  PubMedGoogle Scholar
• 17 Stacy M, Jankovic J. Differential diagnosis of Parkinson's disease and the parkinsonism plus syndromes. Neurol Clin 1992; 10 (2) 341-359
  PubMedGoogle Scholar
• 18 Winter Y, Bezdolnyy Y, Katunina E , et al. Incidence of Parkinson's disease and atypical parkinsonism: Russian population-based study. Mov Disord 2010; 25 (3) 349-356
  CrossrefPubMedGoogle Scholar
• 19 Osaki Y, Morita Y, Kuwahara T, Miyano I, Doi Y. Prevalence of Parkinson's disease and atypical parkinsonian syndromes in a rural Japanese district. Acta Neurol Scand 2011; 124 (3) 182-187
  CrossrefPubMedGoogle Scholar
• 20 Wenning GK, Litvan I, Jankovic J , et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998; 64 (2) 184-189
  CrossrefPubMedGoogle Scholar
• 21 Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration. A clinical study of 36 cases. Brain 1994; 117 (Pt 5) 1183-1196
  CrossrefPubMedGoogle Scholar
• 22 DePold Hohler A, Ransom BR, Chun MR, Tröster AI, Samii A. The youngest reported case of corticobasal degeneration. Parkinsonism Relat Disord 2003; 10 (1) 47-50
  CrossrefPubMedGoogle Scholar
• 23 Litvan I, Grimes DA, Lang AE. Phenotypes and prognosis: clinicopathologic studies of corticobasal degeneration. Adv Neurol 2000; 82: 183-196
  PubMedGoogle Scholar
• 24 Kompoliti K, Goetz CG, Boeve BF , et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 1998; 55 (7) 957-961
  CrossrefPubMedGoogle Scholar
• 25 Watts RMS, Richardson EP. Corticobasal ganglionic degenereration. Oxford: Butterworth-Heinemann; 1994
  Google Scholar
• 26 Murray R, Neumann M, Forman MS , et al. Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology 2007; 68 (16) 1274-1283
  CrossrefPubMedGoogle Scholar
• 27 Smith TW, Lippa CF, de Girolami U. Immunocytochemical study of ballooned neurons in cortical degeneration with neuronal achromasia. Clin Neuropathol 1992; 11 (1) 28-35
  PubMedGoogle Scholar
• 28 Lewis J, McGowan E, Rockwood J , et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 2000; 25 (4) 402-405
  CrossrefPubMedGoogle Scholar
• 29 Ishizawa K, Dickson DW. Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration. J Neuropathol Exp Neurol 2001; 60 (6) 647-657
  CrossrefPubMedGoogle Scholar
• 30 Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 2010; 68 (1) 19-31
  CrossrefPubMedGoogle Scholar
• 31 Ittner LM, Ke YD, Delerue F , et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010; 142 (3) 387-397
  CrossrefPubMedGoogle Scholar
• 32 Hoover BR, Reed MN, Su J , et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010; 68 (6) 1067-1081
  CrossrefPubMedGoogle Scholar
• 33 Baker M, Litvan I, Houlden H , et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999; 8 (4) 711-715
  CrossrefPubMedGoogle Scholar
• 34 Houlden H, Baker M, Morris HR , et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001; 56 (12) 1702-1706
  CrossrefPubMedGoogle Scholar
• 35 Bugiani O, Murrell JR, Giaccone G , et al. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol 1999; 58 (6) 667-677
  CrossrefPubMedGoogle Scholar
• 36 Spillantini MG, Yoshida H, Rizzini C , et al. A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Ann Neurol 2000; 48 (6) 939-943
  CrossrefPubMedGoogle Scholar
• 37 Höglinger GU, Melhem NM, Dickson DW , et al; PSP Genetics Study Group. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 2011; 43 (7) 699-705
  CrossrefPubMedGoogle Scholar
• 38 Unterberger U, Höftberger R, Gelpi E, Flicker H, Budka H, Voigtländer T. Endoplasmic reticulum stress features are prominent in Alzheimer disease but not in prion diseases in vivo. J Neuropathol Exp Neurol 2006; 65 (4) 348-357
  CrossrefPubMedGoogle Scholar
• 39 Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary parkinsonisms. Mov Disord 2011; 26 (6) 1083-1095
  CrossrefPubMedGoogle Scholar
• 40 Spina S, Murrell JR, Huey ED , et al. Corticobasal syndrome associated with the A9D Progranulin mutation. J Neuropathol Exp Neurol 2007; 66 (10) 892-900
  CrossrefPubMedGoogle Scholar
• 41 Masellis M, Momeni P, Meschino W , et al. Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. Brain 2006; 129 (Pt 11) 3115-3123
  CrossrefPubMedGoogle Scholar
• 42 Fekete R, Bainbridge M, Baizabal-Carvallo JF , et al. Exome sequencing in familial corticobasal degeneration. Parkinsonism Relat Disord 2013; 19 (11) 1049-1052
  CrossrefPubMedGoogle Scholar
• 43 Higgins JJ, Litvan I, Nee LE, Loveless JM. A lack of the R406W tau mutation in progressive supranuclear palsy and corticobasal degeneration. Neurology 1999; 52 (2) 404-406
  CrossrefPubMedGoogle Scholar
• 44 Witman GB, Cleveland DW, Weingarten MD, Kirschner MW. Tubulin requires tau for growth onto microtubule initiating sites. Proc Natl Acad Sci U S A 1976; 73 (11) 4070-4074
  CrossrefPubMedGoogle Scholar
• 45 Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 1986; 261 (13) 6084-6089
  PubMedGoogle Scholar
• 46 Fahn SJJ, Hallett M. Principles and Practice of Movement Disorders. 2nd ed. Amsterdam: Elsevier; 2011
  Google Scholar
• 47 Reich SG, Grill SE. Corticobasal degeneration. Curr Treat Options Neurol 2009; 11 (3) 179-185
  CrossrefPubMedGoogle Scholar
• 48 Kumar RBC, Pollanen M, Lang AE. Corticobasal Degeneration. 3rd ed. Baltimore: Lippincott Williams & Wilkins;
  Google Scholar
• 49 Stover NP, Watts RL. Corticobasal degeneration. Semin Neurol 2001; 21 (1) 49-58
  Article in Thieme ConnectPubMedGoogle Scholar
• 50 Constantinescu R, Richard I, Kurlan R. Levodopa responsiveness in disorders with parkinsonism: a review of the literature. Mov Disord 2007; 22 (15) 2141-2148 , quiz 2295
  CrossrefPubMedGoogle Scholar
• 51 Frucht S, Fahn S, Chin S, Dhawan V, Eidelberg D. Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration. Mov Disord 2000; 15 (2) 340-343
  CrossrefPubMedGoogle Scholar
• 52 Hassan A, Whitwell JL, Boeve BF , et al. Symmetric corticobasal degeneration (S-CBD). Parkinsonism Relat Disord 2010; 16 (3) 208-214
  CrossrefPubMedGoogle Scholar
• 53 Müller J, Seppi K, Stefanova N, Poewe W, Litvan I, Wenning GK. Freezing of gait in postmortem-confirmed atypical parkinsonism. Mov Disord 2002; 17 (5) 1041-1045
  CrossrefPubMedGoogle Scholar
• 54 Factor SA, Higgins DS, Qian J. Primary progressive freezing gait: a syndrome with many causes. Neurology 2006; 66 (3) 411-414
  CrossrefPubMedGoogle Scholar
• 55 Lee SE, Rabinovici GD, Mayo MC , et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol 2011; 70 (2) 327-340
  CrossrefPubMedGoogle Scholar
• 56 Stamelou M, Alonso-Canovas A, Bhatia KP. Dystonia in corticobasal degeneration: a review of the literature on 404 pathologically proven cases. Mov Disord 2012; 27 (6) 696-702
  CrossrefPubMedGoogle Scholar
• 57 Vanek ZF, Jankovic J. Dystonia in corticobasal degeneration. Adv Neurol 2000; 82: 61-67
  PubMedGoogle Scholar
• 58 Godeiro-Junior C, Felício AC, Barsottini OG , et al. Clinical features of dystonia in atypical parkinsonism. Arq Neuropsiquiatr 2008; 66 (4) 800-804
  CrossrefPubMedGoogle Scholar
• 59 Riley DE, Lang AE, Lewis A , et al. Cortical-basal ganglionic degeneration. Neurology 1990; 40 (8) 1203-1212
  CrossrefPubMedGoogle Scholar
• 60 Thompson PD, Day BL, Rothwell JC, Brown P, Britton TC, Marsden CD. The myoclonus in corticobasal degeneration. Evidence for two forms of cortical reflex myoclonus. Brain 1994; 117 (Pt 5) 1197-1207
  CrossrefPubMedGoogle Scholar
• 61 Ling H, O'Sullivan SS, Holton JL , et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010; 133 (Pt 7) 2045-2057
  CrossrefPubMedGoogle Scholar
• 62 Chen R, Ashby P, Lang AE. Stimulus-sensitive myoclonus in akinetic-rigid syndromes. Brain 1992; 115 (Pt 6) 1875-1888
  CrossrefPubMedGoogle Scholar
• 63 Thompson PD, Shibasaki H. Myoclonus in corticobasal degeneration and other neurodegenerations. Adv Neurol 2000; 82: 69-81
  PubMedGoogle Scholar
• 64 Müller J, Wenning GK, Verny M , et al. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol 2001; 58 (2) 259-264
  CrossrefPubMedGoogle Scholar
• 65 Rivaud-Péchoux S, Vidailhet M, Gallouedec G, Litvan I, Gaymard B, Pierrot-Deseilligny C. Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. Neurology 2000; 54 (5) 1029-1032
  CrossrefPubMedGoogle Scholar
• 66 Vidailhet M, Rivaud-Péchoux S. Eye movement disorders in corticobasal degeneration. Adv Neurol 2000; 82: 161-167
  PubMedGoogle Scholar
• 67 Boxer AL, Garbutt S, Seeley WW , et al. Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease. Arch Neurol 2012; 69 (4) 509-517
  CrossrefPubMedGoogle Scholar
• 68 Vidailhet M, Rivaud S, Gouider-Khouja N , et al. Eye movements in parkinsonian syndromes. Ann Neurol 1994; 35 (4) 420-426
  CrossrefPubMedGoogle Scholar
• 69 Heuer HW, Mirsky JB, Kong EL , et al. Antisaccade task reflects cortical involvement in mild cognitive impairment. Neurology 2013; 81 (14) 1235-1243
  CrossrefPubMedGoogle Scholar
• 70 Rivaud-Péchoux S, Vidailhet M, Brandel JP, Gaymard B. Mixing pro- and antisaccades in patients with parkinsonian syndromes. Brain 2007; 130 (Pt 1) 256-264
  PubMedGoogle Scholar
• 71 Lang AERD, Bergeron C. Cortical-Basal Ganglionic Degeneration. Philadelphia: WB Saunders; 1994
  Google Scholar
• 72 Bak TH, Hodges JR. Corticobasal degeneration: clinical aspects. Handb Clin Neurol 2008; 89: 509-521
  PubMedGoogle Scholar
• 73 Leiguarda R, Merello M, Balej J. Apraxia in corticobasal degeneration. Adv Neurol 2000; 82: 103-121
  PubMedGoogle Scholar
• 74 Leiguarda R, Lees AJ, Merello M, Starkstein S, Marsden CD. The nature of apraxia in corticobasal degeneration. J Neurol Neurosurg Psychiatry 1994; 57 (4) 455-459
  CrossrefPubMedGoogle Scholar
• 75 Zadikoff C, Lang AE. Apraxia in movement disorders. Brain 2005; 128 (Pt 7) 1480-1497
  CrossrefPubMedGoogle Scholar
• 76 Lang AE. Cortical basal ganglionic degeneration presenting with “progressive loss of speech output and orofacial dyspraxia.”. J Neurol Neurosurg Psychiatry 1992; 55 (11) 1101
  PubMedGoogle Scholar
• 77 Huey ED, Pardini M, Cavanagh A , et al. Association of ideomotor apraxia with frontal gray matter volume loss in corticobasal syndrome. Arch Neurol 2009; 66 (10) 1274-1280
  PubMedGoogle Scholar
• 78 Pharr V, Uttl B, Stark M, Litvan I, Fantie B, Grafman J. Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy. Neurology 2001; 56 (7) 957-963
  CrossrefPubMedGoogle Scholar
• 79 Black SE. Aphasia in corticobasal degeneration. Adv Neurol 2000; 82: 123-133
  PubMedGoogle Scholar
• 80 Grimes DA, Lang AE, Bergeron CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999; 53 (9) 1969-1974
  CrossrefPubMedGoogle Scholar
• 81 Frattali CM, Grafman J, Patronas N, Makhlouf F, Litvan I. Language disturbances in corticobasal degeneration. Neurology 2000; 54 (4) 990-992
  CrossrefPubMedGoogle Scholar
• 82 Josephs KA, Duffy JR, Strand EA , et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006; 129 (Pt 6) 1385-1398
  CrossrefPubMedGoogle Scholar
• 83 Biran I, Chatterjee A. Alien hand syndrome. Arch Neurol 2004; 61 (2) 292-294
  CrossrefPubMedGoogle Scholar
• 84 Carrilho PE, Caramelli P, Cardoso F, Barbosa ER, Buchpiguel CA, Nitrini R. Involuntary hand levitation associated with parietal damage: another alien hand syndrome. Arq Neuropsiquiatr 2001; 59 (3-A): 521-525
  CrossrefPubMedGoogle Scholar
• 85 Brainin M, Seiser A, Matz K. The mirror world of motor inhibition: the alien hand syndrome in chronic stroke. J Neurol Neurosurg Psychiatry 2008; 79 (3) 246-252
  CrossrefPubMedGoogle Scholar
• 86 Fitzgerald DB, Drago V, Jeong Y, Chang YL, White KD, Heilman KM. Asymmetrical alien hands in corticobasal degeneration. Mov Disord 2007; 22 (4) 581-584
  CrossrefPubMedGoogle Scholar
• 87 Denny-Brown D. The nature of apraxia. J Nerv Ment Dis 1958; 126 (1) 9-32
  CrossrefPubMedGoogle Scholar
• 88 Rajagopal R, Bateman R, Van Stavern GP. Visual involvement in corticobasal syndrome. J Neuroophthalmol 2012; 32 (4) 338-340
  CrossrefPubMedGoogle Scholar
• 89 Tang-Wai DF, Josephs KA, Boeve BF, Dickson DW, Parisi JE, Petersen RC. Pathologically confirmed corticobasal degeneration presenting with visuospatial dysfunction. Neurology 2003; 61 (8) 1134-1135
  CrossrefPubMedGoogle Scholar
• 90 Pillon B, Blin J, Vidailhet M , et al. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer's disease. Neurology 1995; 45 (8) 1477-1483
  CrossrefPubMedGoogle Scholar
• 91 Litvan I, Cummings JL, Mega M. Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 1998; 65 (5) 717-721
  CrossrefPubMedGoogle Scholar
• 92 Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997; 48 (5) (Suppl. 06) S10-S16
  PubMedGoogle Scholar
• 93 Cummings JL, Litvan I. Neuropsychiatric aspects of corticobasal degeneration. Adv Neurol 2000; 82: 147-152
  PubMedGoogle Scholar
• 94 Cummings JL, Diaz C, Levy M, Binetti G, Litvan I. Neuropsychiatric Syndromes in Neurodegenerative Disease: Frequency and Signficance. Semin Clin Neuropsychiatry 1996; 1 (4) 241-247
  PubMedGoogle Scholar
• 95 Santamaría J, Tolosa E, Valles A. Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 1986; 36 (8) 1130-1133
  CrossrefPubMedGoogle Scholar
• 96 Blin J, Vidailhet MJ, Pillon B, Dubois B, Feve JR, Agid Y. Corticobasal degeneration: decreased and asymmetrical glucose consumption as studied with PET. Mov Disord 1992; 7 (4) 348-354
  CrossrefPubMedGoogle Scholar
• 97 Juh R, Pae CU, Kim TS, Lee CU, Choe B, Suh T. Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis. Neurosci Lett 2005; 383 (1-2) 22-27
  CrossrefPubMedGoogle Scholar
• 98 Zhao P, Zhang B, Gao S. 18F-FDG PET study on the idiopathic Parkinson's disease from several parkinsonian-plus syndromes. Parkinsonism Relat Disord 2012; 18 (Suppl. 01) S60-S62
  PubMedGoogle Scholar
• 99 Vandenberghe R, Adamczuk K, Van Laere K. The interest of amyloid PET imaging in the diagnosis of Alzheimer's disease. Curr Opin Neurol 2013; 26 (6) 646-655
  CrossrefPubMedGoogle Scholar
• 100 Josephs KA, Whitwell JL, Dickson DW , et al. Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging 2008; 29 (2) 280-289
  CrossrefPubMedGoogle Scholar
• 101 Gröschel K, Hauser TK, Luft A , et al. Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. Neuroimage 2004; 21 (2) 714-724
  CrossrefPubMedGoogle Scholar
• 102 Tedeschi G, Litvan I, Bonavita S , et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain 1997; 120 (Pt 9) 1541-1552
  CrossrefPubMedGoogle Scholar
• 103 Pirker S, Perju-Dumbrava L, Kovacs GG, Traub-Weidinger T, Asenbaum S, Pirker W. Dopamine D2 receptor SPECT in corticobasal syndrome and autopsy-confirmed corticobasal degeneration. Parkinsonism Relat Disord 2013; 19 (2) 222-226
  CrossrefPubMedGoogle Scholar
• 104 Sajjadi SA, Acosta-Cabronero J, Patterson K, Diaz-de-Grenu LZ, Williams GB, Nestor PJ. Diffusion tensor magnetic resonance imaging for single subject diagnosis in neurodegenerative diseases. Brain 2013; 136 (Pt 7) 2253-2261
  CrossrefPubMedGoogle Scholar
• 105 Hess CP, Christine CW, Apple AC, Dillon WP, Aminoff MJ. Changes in the Thalamus in Atypical Parkinsonism Detected Using Shape Analysis and Diffusion Tensor Imaging. AJNR Am J Neuroradiol 2013;
  PubMedGoogle Scholar
• 106 van de Wassenberg WJ, van der Hoeven JH, Leenders KL, Maurits NM. 128-channel somatosensory evoked potentials in the differential diagnosis of parkinsonian disorders. Parkinsonism Relat Disord 2009; 15 (8) 564-571
  CrossrefPubMedGoogle Scholar
• 107 Bruns MB, Josephs KA. Neuropsychiatry of corticobasal degeneration and progressive supranuclear palsy. Int Rev Psychiatry 2013; 25 (2) 197-209
  CrossrefPubMedGoogle Scholar
• 108 Urakami K, Mori M, Wada K , et al. A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy. Neurosci Lett 1999; 259 (2) 127-129
  CrossrefPubMedGoogle Scholar
• 109 Mitani K, Furiya Y, Uchihara T , et al. Increased CSF tau protein in corticobasal degeneration. J Neurol 1998; 245 (1) 44-46
  PubMedGoogle Scholar
• 110 Arai H, Morikawa Y, Higuchi M , et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun 1997; 236 (2) 262-264
  CrossrefPubMedGoogle Scholar
• 111 Portelius E, Hansson SF, Tran AJ , et al. Characterization of tau in cerebrospinal fluid using mass spectrometry. J Proteome Res 2008; 7 (5) 2114-2120
  CrossrefPubMedGoogle Scholar
• 112 Schoonenboom NS, Reesink FE, Verwey NA , et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012; 78 (1) 47-54
  CrossrefPubMedGoogle Scholar
• 113 Maruyama M, Shimada H, Suhara T , et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013; 79 (6) 1094-1108
  CrossrefPubMedGoogle Scholar
• 114 Ludolph AC, Kassubek J, Landwehrmeyer BG , et al; Reisensburg Working Group for Tauopathies With Parkinsonism. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol 2009; 16 (3) 297-309
  CrossrefPubMedGoogle Scholar
• 115 Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A 1996; 93 (20) 11213-11218
  CrossrefPubMedGoogle Scholar
• 116 Pérez M, Hernández F, Lim F, Díaz-Nido J, Avila J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 2003; 5 (4) 301-308
  PubMedGoogle Scholar
• 117 Brunden KR, Ballatore C, Crowe A, Smith III AB, Lee VM, Trojanowski JQ. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol 2010; 223 (2) 304-310
  CrossrefPubMedGoogle Scholar
• 118 Yanamandra K, Kfoury N, Jiang H , et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 2013; 80 (2) 402-414
  CrossrefPubMedGoogle Scholar